Plasmapheresis eliminates the negative impact of AAV antibodies on micro-dystrophin gene expression following vascular delivery.

1] Departments of Pediatrics and Neurology, The Ohio State University and Nationwide Children's Hospital, Columbus, OH, USA, [2] Centers for Gene Therapy and Vaccines and Immunity at The Research Institute at Nationwide Children's Hospital, Columbus, OH. [3] Integrated Biomedical Science Graduate Program, College of Medicine, The Ohio State University, Columbus, OH.
Molecular Therapy (Impact Factor: 6.43). 10/2013; DOI: 10.1038/mt.2013.244
Source: PubMed

ABSTRACT Duchenne muscular dystrophy (DMD) is a monogenic disease potentially treatable by gene replacement. Use of recombinant adeno-associated virus will ultimately require a vascular approach to broadly transduce muscle. We tested the impact of pre-existing AAV antibodies on micro-dystrophin expression following vascular delivery to non-human primates. Rhesus macaques were treated by isolated limb perfusion via a fluoroscopically guided catheter. In addition to serostatus stratification, the animals were placed into one of three immune suppression groups: no immune suppression, prednisone, and triple immune suppression (prednisone, tacrolimus and mycophenolate mofetil). The animals were analyzed for transgene expression at 3 or 6 months. Micro-dystrophin expression was visualized in AAVrh.74 sero-negative animals (mean 48.0% ± 20.8) that was attenuated in sero-positive animals (19.6 ± 18.7%). Immunosuppression did not affect transgene expression. Importantly, removal of AAV binding antibodies by plasmapheresis in AAV sero-positive animals resulted in high level transduction (60.8 ± 18.0%), which is comparable to that of AAV sero-negative animals (53.7 ± 7.6%). While non-pheresed sero-positive animals demonstrated significantly lower transduction levels (10.1 ± 6.0%). These data support the hypothesis that removal of AAV binding antibodies by plasmapheresis permits successful and sustained gene transfer in the presence of pre-existing immunity (natural infection) to AAV.Molecular Therapy (2013); doi:10.1038/mt.2013.244.


Available from: Louise Rodino-Klapac, Apr 17, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Duchenne muscular dystrophy (DMD) is an inherited, progressive muscle wasting disorder caused by mutations in the dystrophin gene. An increasing variety of approaches are moving towards clinical testing that all aim to restore dystrophin production and to enhance or preserve muscle mass. Gene therapy methods are being developed to replace the defective dystrophin gene or induce dystrophin production from mutant genes. Stem cell approaches are being developed to replace lost muscle cells while also bringing in new dystrophin genes. This review summarizes recent progress in the field with an emphasis on clinical applications.
    06/2014; 2(2):102-112. DOI:10.1007/s40124-014-0044-x
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of adeno-associated virus (AAV) as an efficient, cardiotropic, and safe vector, coupled with the identification of key molecular targets, has placed gene-based therapies within reach of cardiovascular diseases. The purpose of this review is to provide a focused update on the current advances related to AAV-mediated gene therapy in cardiovascular diseases, and particularly in heart failure (HF), wherein gene therapy has recently made important progress. Multiple successful preclinical studies suggest a potential utility of AAV gene therapy for arrhythmias and biological heart pacing, as well as RNA overexpression. Moreover, AAV-mediated overexpression of several molecular targets involved in HF has demonstrated promising results in clinically relevant large animal models. In humans, a safe and successful completion of a phase 2 clinical trial targeting the sarcoplasmic reticulum calcium ATPase pump with AAV has been reported. Serial studies are ongoing to further prove the efficacy of AAV-mediated sarcoplasmic reticulum calcium ATPase pump gene transfer in human HF. Significant progress in clinical translation of AAV-mediated cardiac gene therapy has been achieved in recent years. This will prompt further clinical trials, and positive results could open a new era for cardiac gene therapy.
    Current opinion in cardiology 03/2015; 30(3). DOI:10.1097/HCO.0000000000000159 · 2.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Dysferlinopathies are a family of untreatable muscle disorders caused by mutations in the dysferlin gene. Lack of dysferlin protein results in progressive dystrophy with chronic muscle fiber loss, inflammation, fat replacement, and fibrosis; leading to deteriorating muscle weakness. The objective of this work is to demonstrate efficient and safe restoration of dysferlin expression following gene therapy treatment.Methods Traditional gene therapy is restricted by the packaging capacity limit of adeno-associated virus (AAV), however, use of a dual vector strategy allows for delivery of over-sized genes, including dysferlin. The two vector system (AAV.DYSF.DV) packages the dysferlin cDNA utilizing AAV serotype rh.74 through the use of two discrete vectors defined by a 1 kb region of homology. Delivery of AAV.DYSF.DV via intramuscular and vascular delivery routes in dysferlin deficient mice and nonhuman primates was compared for efficiency and safety.ResultsTreated muscles were tested for dysferlin expression, overall muscle histology, and ability to repair following injury. High levels of dysferlin overexpression was shown for all muscle groups treated as well as restoration of functional outcome measures (membrane repair ability and diaphragm specific force) to wild-type levels. In primates, strong dysferlin expression was demonstrated with no safety concerns.InterpretationTreated muscles showed high levels of dysferlin expression with functional restoration with no evidence of toxicity or immune response providing proof of principle for translation to dysferlinopathy patients.
    03/2015; 2(3). DOI:10.1002/acn3.172